Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial
Clayton AH, Althof SE, Kingsberg S, et al. Women's Health 2016;12:325-337.
What it found
For the 1.25 mg and 1.75 mg groups pooled versus placebo: satisfying sexual events rose by 0.7 versus 0.2 per month, the Female Sexual Function Index rose by 3.6 versus 1.9 points, and the distress score fell by 11.1 versus 6.8 points. Side effects were nausea, flushing and headache.
Limitations
Premenopausal women with female sexual dysfunction. Efficacy data for 327 women. The absolute gain in satisfying events was small. Several authors were employed by the developer.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.